All In Biotech

Free tool

FAERS Monitor: Gilotrif

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 201292 or its brand name (Gilotrif, Afatinib Dimaleate). Reports on generic versions are filed under their own applications.

Reports

6,622

Serious

5,732

87% of reports

Hospitalization

2,095

Death reported

1,475

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea2,128
  • malignant neoplasm progression1,696
  • rash884
  • death524
  • nausea488
  • stomatitis486
  • decreased appetite450
  • vomiting410
  • paronychia355
  • dehydration317
  • fatigue292
  • off label use283
  • metastases to central nervous system270
  • asthenia238
  • drug ineffective234

Reports by year received

View as table
YearReports
20125
2013122
2014503
2015744
2016794
2017731
2018936
2019645
2020582
2021456
2022343
2023283
2024214
2025161
2026103

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,537 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
paronychiaSignal355279.0251.090,169
metastases to central nervous systemSignal27067.960.317,367
malignant neoplasm progressionSignal1,69653.551.386,247
stomatitisSignal48625.623.511,428
diarrhoeaSignal2,12810.510.118,803
dehydrationSignal3177.66.81,806
rashSignal8846.56.14,145
decreased appetiteSignal4506.25.61,959
vomitingSignal4102.82.5473
astheniaSignal2382.01.8122
nausea4882.01.8237
death5241.91.8245
fatigue2921.21.19
off label use2831.00.90
drug ineffective2340.60.584

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.